資料載入中.....
|
請使用永久網址來引用或連結此文件:
https://ir.cnu.edu.tw/handle/310902800/27070
|
| 標題: | In vitro and in vivo therapeutics of β-thujaplicin on LPS-induced inflammation in macrophages and septic shock in mice |
| 作者: | Shih, MF
Chen, LY
Tsai, PJ
Cherng, JY. |
| 貢獻者: | 藥學系 |
| 關鍵字: | inflammation
beta-thujaplicin
iNOS
TNF-alpha
septic shock |
| 日期: | 2011-01 |
| 上傳時間: | 2013-10-25 15:33:46 (UTC+8) |
| 出版者: | Biolife Sas |
| 摘要: | beta-thujaplicin, an active constituent from Chamaecyparis obtusa, has been shown to have acaricidal and antimicrobial effects. Very few studies have focused on the potential of the anti-inflammatory effect of beta-thujaplicin. Moreover, its capability of inhibiting inflammatory mediators e.g. TNF-alpha gene transcription, nitric oxide (NO) and prostaglandin E2, remains unknown. Besides those molecular mechanisms behind the anti-inflammatory effect of beta-thujaplicin, solid proof of its effectiveness in vivo has not yet been studied. In our study, in vitro effects of beta-thujaplicin were verified on RAW 264.7 macrophages which were stimulated by LPS. Indomethacin was used as a positive control. The inducible NO production after stimulation was measured by Griess reagent. PGE2, IL-6 and TNF-alpha were measured by ELISA methods. Protein expressions of iNOS, COX2, and NF-kappa B were evaluated by Western blotting. Septic ICR mice were administered 20 mg/kg of LPS and then the mortality rate was monitored. Within the concentration range which was devoid of cytotoxicty, beta-thujaplicin exhibited a clear dose-dependent inhibition on LPS-induced NO production. Furthermore, beta-thujaplicin inhibited LPS-induced PGE2, IL-6, and TNF-alpha production as well as iNOS, COX2, and NF-kappa B protein expression more substantially potent than indomethacin. In agreement with the in vitro study, beta-thujaplicin was shown to be effective in vivo for inhibiting LPS-induced NO and TNF-alpha production and a significant decrease in mortality rate of mice suffering from septic shock was observed. This study demonstrates the potential of beta-thujaplicin in treatment of inflammation and sepsis. These effects occur through an efficient blockage of TNF-alpha and iNOS production. beta-thujaplicin efficacy is comparable to that of indomethacin thus it can be a substitution but bear less depletion of PGE2, making this compound very promising in clinical applications |
| 關聯: | International Journal Immunopathol pharmacology, 25(1), pp.39-48 |
| 顯示於類別: | [藥學系(所)] 期刊論文
|
文件中的檔案:
| 檔案 |
描述 |
大小 | 格式 | 瀏覽次數 |
|---|
| index.html | | 0Kb | HTML | 1998 | 檢視/開啟 |
|
在CNU IR中所有的資料項目都受到原著作權保護.
|
